Background
==========

Despite significant advances in our ability to treat high BP over the last few decades, HT continues to be a major public health problem.[@b1-ppa-11-363]

A total of 44% of strokes and 47% of cardiac deaths are attributed to suboptimal BP control. Despite the variety of antihypertensive medications available, including combination drugs, HT often remains uncontrolled.[@b2-ppa-11-363] The rate of nonadherence reported in various studies ranges from 10 to 92%.[@b3-ppa-11-363] In developed countries, it is estimated at 50%.[@b4-ppa-11-363] Adherence is typically better in patients with acute disease and becomes worse in chronically ill patients.[@b5-ppa-11-363],[@b6-ppa-11-363] The available studies show that 50% of hypertensive patients discontinue treatment within 12 months of its beginning. Another 30% continue treatment but do not comply fully with the prescribed protocol.[@b7-ppa-11-363] Low adherence to HT management is one of the major contributors to poor BP control.[@b8-ppa-11-363],[@b9-ppa-11-363]

Therefore, it is useful to measure patients' adherence behaviors to provide evidence regarding BP control. Understanding the barriers affecting a patient's ability to adhere to antihypertensive therapy will allow researchers to design effective interventions. Moreover, a better understanding will help evaluate the impact of these interventions on perceived and actual barriers to medication use, adherence rates, and ultimately, patient outcomes.[@b10-ppa-11-363]

The WHO (2003)[@b11-ppa-11-363] identified three groups of factors associated with poor adherence. The first group is associated with the complexity of the disease and its treatment and includes the presence of comorbidities, complications, long disease duration, and the number and frequency of use of prescribed medications. The second group includes intrapersonal factors such as sex, age, self-efficacy, alcohol abuse, and depression. The third group comprises interpersonal factors that include patient--provider communication and social support.[@b12-ppa-11-363] In the literature, the most commonly discussed barriers include depression, lack of social support, geriatric syndrome, and poor quality of life.[@b8-ppa-11-363],[@b9-ppa-11-363] Other significant factors include age, sex, education, race, geographical region of residence, and illness perceptions.[@b13-ppa-11-363]--[@b15-ppa-11-363] Participation in the treatment process is affected positively by knowledge about the illness and acceptance of illness. Some articles have been published on associations between illness acceptance and treatment adherence.[@b16-ppa-11-363]

Acceptance of illness is a complex process that plays a key role in adapting to chronic illness and may be affected by clinical factors, illness symptoms, treatment quality, medication side effects, individual predispositions resulting from imposed limitations, and strategies for coping with the illness.[@b17-ppa-11-363] Illness acceptance engenders a sense of security and mitigates the negative reactions related to the illness and treatment. Better acceptance of illness corresponds not only to a lower intensity of negative emotions and reactions but also to a greater involvement of the patient in the treatment process and to better self-control capabilities.[@b18-ppa-11-363] Higher levels of self-care result in better adherence to pharmacological treatment and better BP control.[@b19-ppa-11-363],[@b20-ppa-11-363]

A previous study on adherence confirmed the correlation between acceptance of illness and adherence to HT treatment but mainly with regard to nonpharmacological measures. Patients' sex and education and the illness duration correlated with adherence to pharmacological and nonpharmacological treatments in HT.[@b18-ppa-11-363]

The aim of this study was to analyze the relationship between selected variables and adherence to pharmacological treatment in patients with HT. The study focused on the role of selected sociodemographic and clinical determinants, including illness acceptance, in HT treatment and on identifying those factors that could be correlated with adherence. The variables studied were as follows: patients' sex, age, marital status, professional activity, duration of illness, HT grade, and the number of drugs prescribed (monotherapy, polytherapy, or polytherapy in one tablet).

Participants and methods
========================

Participants
------------

The study used structured interviews with 707 adult outpatients attending a general practitioners' clinic in Wrocław between February 2014 and April 2015. The inclusion criteria were as follows: age \>18 years, HT diagnosis in line with the guidelines of the ESH,[@b21-ppa-11-363] treatment with at least one hypotensive agent for the past year, and informed consent. Patients diagnosed with other serious diseases (cardiac insufficiency, renal insufficiency, and neoplasms) and severe cardiovascular complications or other severe concomitant diseases, which could affect illness acceptance and adherence to therapeutic guidelines, were excluded from the study due to their complex treatment schemes and the possibility of adverse effects and reactions occurring as a result of being treated with multiple medications. Of the 707 subjects who met the criteria, 87 subjects refused to take part in the study without giving a reason.

Patients were selected by a panel consisting of a physician and a nurse -- specialist in the field of cardiac nursing. All patients received information about the purpose and nature of the study and provided written informed consent to participate. The questions concerned the last 6 months of therapy and were answered directly by the patients. For each patient, at least two BP measurements and a comprehensive physical examination were performed, and patient histories were taken. Whenever systolic and diastolic BP values fell into different categories, the patient was classified into the higher category.

All patients were informed of the purpose and nature of our study and provided their written informed consent to be included in it. All patients completed all questionnaires.

Information concerning the sociodemographic and clinical data come from the outpatients' clinic files.

The sample group was homogeneous and suitable for statistical analysis.

Ethical consideration
---------------------

The study was approved by the Independent Bioethics Committee of the Wroclaw Medical University (approval no KB 136/2015). All participants gave written informed consent after thorough explanation of the procedures involved. The study was carried out in accordance with the tenets of the Declaration of Helsinki.

Measures
--------

The sociodemographic and clinical characteristics recorded included participant's age, sex, marital status, education, professional activity, duration of HT, and the number of prescription medications taken daily.

Instruments
-----------

The following two validated instruments were used: the AIS and the MMAS-8. The scales were distributed by a cardiac nurse in the waiting room of the clinic, but the patients answered the questions themselves.

The AIS was developed by Felton, Revenson, and Hinrichsen and adapted into Polish by Juczyński. The scale evaluates the extent of adaptation to changes resulting from the illness. It comprises eight statements regarding difficulties and limitations imposed by the illness, including the loss of independence, the sense of being dependent on others, and decreased self-esteem. Answers are provided using a 5-item Likert scale, with 1 meaning "strongly agree" and 5 meaning "strongly disagree". The total score, between 8 and 40 points, indicates the acceptance of the illness level, with higher scores denoting more acceptance. The reliability and internal consistency of the Polish version of AIS (Cronbach's alpha 0.82) are similar to those of the original instrument. Participants were categorized as having low or high self-reported acceptance of illness based on their mean AIS score in three consecutive surveys.[@b22-ppa-11-363]

Self-reported medication adherence was assessed using the MMAS-8. The self-reported MMAS-8 tool is simple to administer, reliable, and economical in clinical practice. The MMSA-8 was designed to facilitate the identification of barriers to and behaviors associated with adherence to chronic medication. The tool has been determined to be reliable and significantly associated with BP control in individuals with HT as well as with antihypertensive medication pharmacy fill rates. Scores on the MMAS-8 range from 0 to 8, with scores \<6 reflecting low adherence, 6--\<8 reflecting moderate adherence, and 8 reflecting high adherence.[@b23-ppa-11-363] In this study, the following two dichotomous factors were considered: low-to-moderate adherence (\<8 points in the MMAS-8) and high adherence (8 points in the MMAS-8).

Statistical analysis
--------------------

Correlations between adherence (MMAS-8 scores) and illness acceptance (AIS scores) were analyzed using Spearman's rank correlation coefficients (*ρ*) and significance levels (*P*). Because the data included many dependent observations, gamma values were also calculated. The independence of the cross-tabulated qualitative and ordinal characteristics was verified using Pearson's chi-squared test. In two-by-two tables, Yates' correction for continuity was used.[@b17-ppa-11-363]

Calculations were performed using EXCEL spreadsheets and STATISTICA software (StatSoft Inc., Tulsa, OK, USA).

Results
=======

Patient characteristics
-----------------------

In total, 620 patients (including 333 women) aged between 20 and 86 years (*M*=58, SD =14) and treated for HT participated in the survey. The duration of illness in the group was between 1 and 38 years (*M*=7, SD =8). The patients' basic sociodemographic and clinical characteristics are shown in [Table 1](#t1-ppa-11-363){ref-type="table"}.

Adherence to pharmacological treatment was evaluated using the MMAS-8. The mean score was 7 (range: 0.25--8).

The distributions of AIS and MMAS-8 scores differed significantly from normal. Thus, Spearman's regression analysis (Spearman's rank correlation) was used instead of Pearson's regression analysis.

For the whole studied group of 620 patients, a weak positive correlation was found between adherence and acceptance levels. The variable independence test result was near the statistical significance threshold (*P*=0.062\>0.05). With low-to-moderate acceptance patients and low-to-moderate adherence patients grouped together, the correlation between the analyzed factors was statistically significant ([Table 2](#t2-ppa-11-363){ref-type="table"}).

To determine the strength of correlations between illness acceptance and medication adherence, Spearman's rank correlation coefficients (*ρ*=0.090; *P*=0.024\<0.05) and gamma values (*β*=0.133; *P*\<0.01) were calculated. When adherence and illness acceptance scores were divided into pairs of dichotomous factors, a statistically significant correlation (*P*=0.008) was found ([Table 2](#t2-ppa-11-363){ref-type="table"}).

The high-adherence group comprised a significantly higher percentage of patients with high AIS scores than that of patients with low-to-moderate scores (42.4 vs 31.8%; *P*=0.008\<0.01). The OR shows that high adherence to pharmacological treatment is \>1.5 times as likely to occur in the high acceptance group as in the low-to-moderate acceptance group (OR =1.58, 95% CI 1.14--2.19).

The comparative analysis of the adherence level was based on the selected sociodemographic and clinical variables. The impact of the selected sociodemographic factors on the adherence to the recommendations investigated by means of MMAS-8 questionnaire is presented in [Table 3](#t3-ppa-11-363){ref-type="table"}. A statistically significant relationship was observed between adherence to the recommendations of hypertensive treatment and some factors such as sex, age, education, the stage of the HT, the type of the pharmacological treatment, and the illness acceptance (*P*\<0.05) ([Table 3](#t3-ppa-11-363){ref-type="table"}). For these variables, the OR was calculated.

The results of OR showed that the chance for high adherence in women was 1.5 times lower than in men (32.4 vs 40.8%). The chance for high adherence in patients aged \>65 years was lower than in patients aged \>45 years (OR =0.70), but the impact of age was not statistically significant (OR =0.61--2.08). The chance for high adherence in patients with secondary education was over twice higher than in patients with primary education (OR =2.20) and \>1.5 times higher than in patients with university education (OR =1.88).

The chance for high adherence in patients with HT of stages 3 and 4 according to ESC was \>1.5 times lower than in patients with HT of stage 1 (OR =0.50 and 0.53). The chance for high adherence in patients with monotherapy was \>1.5 times lower than in patients with polytherapy in one tablet (OR =0.60) and even much lower in patients with polytherapy (OR =0.27). The chance for high adherence in patients with high illness acceptance was higher than in patients with low illness acceptance (OR =1.43). However, the 95% CI for OR contained value 1, which meant that the impact of high illness acceptance on high adherence was not statistically significant ([Table 4](#t4-ppa-11-363){ref-type="table"}).

The Mantel--Haenszel OR adjusted for sex, age, illness duration, marital status, professional activity, and polytherapy in one tablet is OR~MH~ =1.63 with a 95% CI of 1.50--1.77. Patients with a high acceptance of illness are \>1.5 times more likely to show high adherence than those with a low illness acceptance level. The adjusted OR~MH~ has a much narrower CI than OR values in other patient subgroups ([Figure 1](#f1-ppa-11-363){ref-type="fig"}) and is further from OR =1, which indicates that the analyzed socioclinical characteristics are confounding variables, affecting the correlation between adherence and acceptance. Adjusting for these variables resulted in a narrower CI for the OR.

In summary, a significant correlation can be seen between acceptance of illness and adherence to pharmacological treatment, though some socioclinical characteristics are equally significant, both for acceptance of illness and for adherence to pharmacological treatment in HT.

Discussion
==========

The understanding of determinants of adherence to pharmacological treatment in HT is key to treatment planning. Effective identification of patients at risk of pharmacological nonadherence might be especially helpful in planning interventions to enhance illness control, prevent complications, improve long-term treatment outcomes, and limit adverse outcomes in these patients. According to published studies, adherence mainly depends on the patients' knowledge and their sociodemographic characteristics, such as sex, age, education, and marital status. Psychosocial factors, which have not been extensively studied until recently, may also have a significant impact on chronic illness management.[@b12-ppa-11-363]--[@b15-ppa-11-363] Researchers have pointed to several such factors, including social support, perception and acceptance of illness, cognitive impairment, and depression.[@b16-ppa-11-363]

The author's own study showed a statistically significant but weak correlation between acceptance of illness and adherence scores, especially in the group of male patients, aged ≥45--65, diagnosed with HT at least 10 years before, marital status, professionally active, and receiving one-tablet polytherapy. Female sex, age \<66 years, shorter duration of illness, higher stage of the HT (third grade ESC and fourth grade ESC), and being treated with polytherapy were found to be confounding variables in terms of the correlation between adherence.

One interesting finding in our study is the lack of significant correlation between adherence to pharmacological treatment and acceptance of illness. In the comparative analysis, the patients with high level of the acceptance of the disease had higher level of adherence into recommendations in MMAs-8 questionnaire. But in the OR analysis, despite the fact that the patients with high illness acceptance got higher pharmacological adherence scores, the results were not statistically significant. The OR shows that high adherence to pharmacological treatment is \>1.5 times as likely to occur in the high acceptance group as in the low-to-moderate acceptance group. Published studies prove that illness perception and attitude toward treatment play an important role in adherence to therapeutic instructions.[@b15-ppa-11-363],[@b24-ppa-11-363],[@b25-ppa-11-363]

Illness acceptance results in a sense of security and mitigates negative emotions related to the illness and treatment. Higher levels of illness acceptance are correlated with a reduction in negative reactions to the illness, which increases the patient's involvement in treatment. In previous studies, acceptance of illness was correlated with better adherence to treatment,[@b16-ppa-11-363] but especially, significant correlations in single-factor analysis were only found with regard to the patients' health-related behaviors.

In a study by Rajpura and Nayak,[@b25-ppa-11-363] multiple-factor analysis showed that perception of illness and attitude toward treatment have a significant influence on adherence scores.[@b25-ppa-11-363] Other researchers have identified self-efficacy and perception of illness as factors affecting adherence to pharmacological treatment.[@b26-ppa-11-363],[@b27-ppa-11-363]

Poor adherence is found in patients who believe that HT medication has adverse effects.[@b28-ppa-11-363] Moreover, improved knowledge of HT may affect patients' acceptance of illness and their beliefs related to the illness and its treatment.[@b2-ppa-11-363],[@b29-ppa-11-363] However, few studies[@b25-ppa-11-363] exist to confirm the correlation between acceptance of illness and adherence to pharmaceutical treatment,[@b16-ppa-11-363] and the available articles mainly focus on AIS in the context of quality of life in chronic illness.[@b30-ppa-11-363]--[@b32-ppa-11-363]

The role of a patient's sex in adherence is often discussed, but so far, contradictory findings have been published. In the author's own study, male sex was found to be a determinant of adherence and illness acceptance. In the literature, contradictory reports can be found on the relationship between sex and adherence. In a study by Hyre et al,[@b33-ppa-11-363] female patients had lower adherence scores, while in a study by Kim et al,[@b34-ppa-11-363] lower adherence was found in black male patients.

Another determinant of higher adherence in the authors' study was age \>66 years. Age \<66 years was a confounder in the correlation of adherence to pharmacological treatment. This study can contribute to the discussion on the relationship between age and adherence. According to some reports, younger patients show better adherence to pharmacological treatment,[@b5-ppa-11-363],[@b35-ppa-11-363] while others state that young age is a determinant of poorer adherence to hypotensive medication.[@b36-ppa-11-363],[@b37-ppa-11-363] Some researchers have also found better adherence among elderly patients.[@b25-ppa-11-363],[@b38-ppa-11-363]--[@b40-ppa-11-363] Nonadherence in younger patients may be due to the lack of persistent symptoms at early stages of the illness or to concerns about medication side effects. The better adherence to treatment found in elderly patients has been explained by the presence of comorbidities, which make the patients perceive themselves as very ill and take the prescribed treatment seriously.[@b37-ppa-11-363]

In the own study, being in a relationship was not regarded as a significant factor increasing adherence. Notably, published articles confirm better adherence found in patients supported by family members and friends.[@b33-ppa-11-363],[@b41-ppa-11-363],[@b42-ppa-11-363] Meinema et al[@b29-ppa-11-363] showed that patients who adhere to treatment typically experience family support, while Maguire et al[@b43-ppa-11-363] reported strong social support enjoyed by high-adherence patients. Patients who receive social support, maintain a healthy diet, and take their medication regularly are capable of recognizing the symptoms of illness exacerbation.[@b44-ppa-11-363]

Illness duration is another factor that may affect adherence. In this study, illness duration exceeding 10 years was correlated with higher adherence scores. Similarly, Hyre et al[@b33-ppa-11-363] reported that a time from HT diagnosis of \<10 years was correlated with lower adherence scores, but these results were not statistically significant. Lee reported a correlation between shorter duration of HT (\<5 years) and poorer adherence to pharmacological treatment. This may be explained by improved awareness and understanding of the illness in patients who have been treated for a longer time. The patients may be better informed on the importance of consistent treatment and the related limitations.[@b33-ppa-11-363] They are more experienced, have established a better physician--patient relationship, and have greater faith in their physician's advice. In addition, they might become more knowledgeable about their own health and the appropriate disease management and control.[@b45-ppa-11-363],[@b46-ppa-11-363] In the literature, studies exist that corroborate our reports of a correlation between longer illness duration and higher adherence scores.[@b33-ppa-11-363],[@b37-ppa-11-363]

Another factor correlated with adherence to treatment is the type and quantity of medication. In this study, combined treatment administered in one tablet was positively correlated with adherence. Other researchers also report that patients show better adherence if they are prescribed one drug or a single daily dose.[@b36-ppa-11-363],[@b41-ppa-11-363] They also found a correlation between adherence and the number of drugs prescribed. Fewer drugs contributed to better adherence.[@b32-ppa-11-363]

Study limitations
=================

One limitation is the fact that the level of adherence in our study was only measured using a direct method based on a self-reported questionnaire. The results were not verified by indirect methods, such as the use of physiological markers, pharmacy records, the measurement of drug concentration in body fluids, the activity of selected biochemical markers of tablets in serum, and drug concentrations in body fluids for monitoring the treatment. The risk of under-or overestimation in this method is connected with the individual variability in drug metabolism, especially in elderly people. The use of the electronic reader is expensive and does not consider the case of the opening of the box without taking the medicine. However, it is the most accurate method of the evaluation of the adherence.[@b47-ppa-11-363]

Another limitation could be the fact that patients' satisfaction with the treatment process and their knowledge on the illness were not assessed.

Conclusion
==========

Findings from this study provide clear evidence to physicians and health care policymakers that there is no single factor that can be deemed solely responsible for influencing drug adherence among patients, as the problem of nonadherence is multifactorial.

Acceptance of illness is correlated with adherence to pharmacological treatment, and consideration should be given to more widespread assessment of illness acceptance in daily practice.

Male sex, higher education, lower stage of HT (according the grade ESC), and receiving one-tablet polytherapy are significant determinants of adherence to pharmacological treatment in HT.

Implication for practice
------------------------

The problem of patients' poor adherence to therapeutic recommendations in long-term treatment requires special interventions. Daily medical practice should include continuous evaluation of illness acceptance and adherence to HT treatment, so that nonadhering patients can be given additional attention. Patients need information to understand the nature of their illness and the importance of adherence to treatment. Each visit should be accompanied by counseling to improve adherence to treatment, as well as to enhance acceptance and perception of the illness. Health care providers need to focus on patients' behaviors that may interfere with adherence to treatment in order to gain control of HT in the community. Health care professionals should identify the available (viable) strategies for increasing adherence in their daily practice.
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###### 

Characteristics of the 620 hypertensive patients

  Characteristics                                               N     \%
  ------------------------------------------------------------- ----- ------
  Female                                                        333   53.7
  Age (years)                                                         
   20--45                                                       133   21.5
   46--65                                                       307   49.5
    ≥66                                                         180   29.0
  Duration of the illness (years)                                     
   1--5                                                         231   37.2
   5.1--10                                                      192   31.0
   \>10                                                         197   31.8
  Living alone                                                  197   31.0
  Education                                                           
   None or primary                                              187   30.2
   High school                                                  273   44.0
   College/university                                           160   25.8
  Professionally active                                         286   46.1
  BMI (kg/m^2^)                                                       
   \<20.0                                                       161   26.0
   20--25                                                       245   39.5
   \>25                                                         214   34.5
  ESC hypertension grade (mean value of the two measurements)         
   120--129 and/or 80--84                                       15    2.4
   130--139 and/or 85--89                                       186   30.0
   140--159 and/or 90--99                                       287   46.3
   160--169 and/or 100--109                                     132   21.3
  Hypertension treatment                                              
   Monotherapy                                                  128   20.6
   Polytherapy in one tablet                                    91    14.7
   Polytherapy                                                  401   64.7
  Way of taking medication                                            
   Directly from the blister                                    450   72.6
   From daily dispenser box                                     27    4.4
   From weekly dispenser box                                    22    3.5
   Administered by a caregiver                                  121   19.5

**Abbreviations:** BMI, body mass index; ESC, European Society of Cardiology.

###### 

Numbers (percentages) of patients (out of 620) in the acceptance of illness and adherence subgroups (based on AIS and MMAS-8 scores), chi-squared test results, and OR values with 95% CIs

  Adherence score (MMAS-8)           Acceptance of illness score, n (%)   
  ---------------------------------- ------------------------------------ ------------
  1\. Low to moderate                217 (68.2)                           174 (57.6)
  2\. High                           101 (31.8)                           128 (42.4)
  *P*=0.008; OR =1.58 (1.14--2.19)                                        

**Notes:** Use of the ©MMAS is protected by US and International copyright laws. The permission for use is required. A license agreement is available from Donald E Morisky, MMAS Research (MORISKY) 16636 159th Place SE, Renton, WA 98058 USA, <dmorisky@gmail.com>.

**Abbreviations:** AIS, Acceptance of Illness Scale; MMAS-8, 8-item Morisky Medication Adherence Scale; OR, odds ratio.

###### 

Number (percentage) of 620 hypertensive patients in the subgroups with different levels of adherence (MMAS-8) and selected features of sociodemographic and clinical data and univariate analysis

  Variables                                                            MMAS-8 level (v56), n (%)                 
  -------------------------------------------------------------------- --------------------------- ------------- -------------
  Sex                                                                                                            
  1\. Female                                                           86 (47.0)                   111 (53.4)    136 (59.4)
  2\. Male                                                             97 (53.0)                   97 (46.6)     93 (40.6)
  Pearson chi-square: *P*=0.043, Spearman's *ρ*=−0.101 (*P*=0.012)                                               
  Age (years)                                                                                                    
  1\. 20--45                                                           53 (29.0)                   34 (16.3)     46 (20.1)
  2\. 46--65                                                           96 (52.4)                   95 (45.7)     116 (50.6)
  3\. ≥66                                                              34 (18.6)                   79 (38.0)     67 (29.3)
  Pearson chi-square: *P*\<0.001, Spearman's *ρ*=0.098 (*P*=0.015)                                               
  Duration of the illness (years)                                                                                
  1\. 0.2--5                                                           79 (43.2)                   66 (31.7)     86 (37.6)
  2\. 5.1--10                                                          63 (34.4)                   60 (28.9)     69 (30.1)
  3\. \>10                                                             41 (22.4)                   82 (39.4)     74 (32.3)
  Pearson chi-square: *P*=0.010, Spearman's *ρ*=0.064 (*P*=0.113)                                                
  Relationship status                                                                                            
  1\. In a relationship                                                84 (64.1%)                  119 (61.3%)   123 (63.7%)
  2\. Living alone                                                     47 (35.9%)                  75 (38.7%)    70 (36.3%)
  Pearson chi-square: *P*=0.842, Spearman's *ρ*=−0.001 (*P*=0.977)                                               
  Education                                                                                                      
  1\. Primary                                                          68 (37.1)                   71 (34.1)     48 (21.0)
  2\. High school                                                      79 (43.2)                   76 (36.5)     118 (51.5)
  3\. College/university                                               36 (19.7)                   61 (29.3)     63 (27.5)
  Pearson chi-square: *P*\<0.001, S pearman's *ρ*=0.132 (*P*=0.001)                                              
  Professional activity                                                                                          
  1\. Active                                                           95 (51.9)                   93 (44.7)     98 (42.8)
  2\. Not active                                                       88 (48.1)                   115 (55.3)    131 (57.2)
  Pearson chi-square: *P*=0.161, Spearman's *ρ*=0.072 (*P*=0.074)                                                
  ESC hypertension grade                                                                                         
  1\. 120--129 and/or 80--84                                           20 (10.9)                   15 (7.2)      35 (15.3)
  2\. 130--139 and/or 85--89                                           36 (19.7)                   43 (20.7)     52 (22.7)
  3\. 140--159 and/or 90--99                                           98 (53.6)                   93 (44.7)     96 (41.9)
  4\. 160--169 and/or 100--109                                         29 (15.8)                   57 (27.4)     46 (20.1)
  Pearson chi-square: *P*=0.012, Spearman's *ρ*=−0.037 (*P*=0.057)                                               
  Way of taking medication                                                                                       
  1\. Directly from the blister                                        23 (12.6)                   27 (13.0)     26 (11.4)
  2\. From a dispenser box                                             20 (10.9)                   37 (17.8)     41 (17.9)
  3\. Administered by a caregiver                                      140 (76.5)                  144 (69.2)    162 (70.7)
  Pearson chi-square: *P*=0.292, Spearman's *ρ*=−0.038 (*P*=0.347)                                               
  Hypertension treatment                                                                                         
  1\. Monotherapy                                                      18 (9.8)                    13 (6.2)      7 (3.1)
  2\. Polytherapy                                                      115 (62.8)                  117 (56.3)    116 (50.6)
  3\. Polytherapy in one tablet                                        50 (27.3)                   78 (37.5)     106 (46.3)
  Pearson chi-square: *P*\<0.001, S pearman's *ρ*=0.176 (*P*\<0.001)                                             
  AIS level                                                                                                      
  1\. Low                                                              20 (10.9)                   17 (8.2)      19 (8.3)
  2\. Medium                                                           80 (43.7)                   100 (48.1)    82 (35.8)
  3\. High                                                             83 (45.4)                   91 (43.7)     128 (55.9)
  Pearson chi-square: *P*=0.062, Spearman's *ρ*=0.090 (*P*=0.024)                                                

**Notes:** Use of the ©MMAS is protected by US and International copyright laws. The permission for use is required. A license agreement is available from Donald E Morisky, MMAS Research (MORISKY) 16636 159th Place SE, Renton, WA 98058 USA, <dmorisky@gmail.com>.

**Abbreviations:** AIS, Acceptance of Illness Scale; ESC, European Society of Cardiology; MMAS-8, 8-item Morisky Medication Adherence Scale.

###### 

OR for the significant variable in comparative analysis of the adherence level with the selected sociodemographic and clinical determinants

  Variable                          Adherence level, n (%)   OR (95% CI)   
  --------------------------------- ------------------------ ------------- -------------------
  Sex                                                                      
   Male                             136 (40.8)               197 (59.2)    1.00 (ref)
   Female                           93 (32.4)                194 (67.6)    0.69 (0.50--0.97)
  Age (years)                                                              
   20--45                           37 (66.1)                19 (33.9)     1.00 (ref)
   46--65                           180 (68.7)               82 (31.3)     1.13 (0.61--2.08)
    ≥66                             174 (57.6)               128 (42.4)    0.70 (0.38--1.27)
  Education                                                                
   Primary                          48 (25.7)                139 (74.3)    1.00 (ref)
   High school                      118 (43.2)               155 (56.8)    2.20 (1.47--3.31)
   College/university               63 (39.4)                97 (60.6)     1.88 (1.19--2.97)
  ESC hypertension grade                                                   
   120--129 and/or 80--84           35 (50.0)                35 (50.0)     1.00 (ref)
   130--139 and/or 85--89           52 (39.7)                79 (60.3)     0.66 (0.37--1.18)
   140--159 and/or 90--99           96 (33.4)                191 (66.6)    0.50 (0.30--0.85)
   160--169 and/or 100--109         46 (34.8)                86 (65.2)     0.53 (0.30--0.96)
  Duration of the illness (years)                                          
   0.2--5                           145 (74.9)               222 (60.3)    1.00 (ref)
   5.1--10                          123 (63.3)               55 (59.8)     1.02 (0.64--1.63)
   \>10                             123 (61.8)               114 (71.3)    1.93 (1.07--2.92)
  Hypertension treatment                                                   
   Polytherapy                      7 (18.4)                 31 (81.6)     1.00 (ref)
   Monotherapy                      116 (33.3)               232 (66.7)    0.60 (0.43--0.85)
   Polytherapy in one tablet        106 (45.3)               128 (54.7)    0.27 (0.12--0.64)
  Illness acceptance                                                       
   Low (N=56)                       19 (33.9)                37 (66.1)     1.00 (ref)
   Medium (N=262)                   82 (31.3)                180 (68.7)    0.89 (0.48--1.64)
   High (N=302)                     128 (42.4)               174 (57.6)    1.43 (0.78--2.61)

**Abbreviations:** ESC, European Society of Cardiology; OR, odds ratio; ref, reference.
